• No results found

University of Groningen Biomarkers in stable and acute exacerbations of COPD Prins, Hendrik J

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Biomarkers in stable and acute exacerbations of COPD Prins, Hendrik J"

Copied!
8
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Biomarkers in stable and acute exacerbations of COPD Prins, Hendrik J

DOI:

10.33612/diss.136484081

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Prins, H. J. (2020). Biomarkers in stable and acute exacerbations of COPD. University of Groningen. https://doi.org/10.33612/diss.136484081

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Biomarkers in stable and acute

exacerbations of COPD

(3)

ISBN: 978-94-034-2679-2 Ontwerp cover: Ria van der Linden

Lay-out by: ProefschriftMaken || www.proefschriftmaken.nl Printed by: ProefschriftMaken || www.proefschriftmaken.nl

(4)

Biomarkers in stable and acute

exacerbations of COPD

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op maandag 16 november 2020 om 14.30 uur

door

Hendrik Johannes Prins

geboren op 22 november 1982 te Zwolle

(5)

Promotor

Prof. dr. T.S. van der Werf

Copromotor

Dr. W.G. Boersma

Beoordelingscommissie

Prof. dr. A.W. Friedrich Prof. dr. J.M. Prins Prof. dr. P.J. Wijkstra

(6)
(7)
(8)

Table of contents

Chapter 1: General introduction 9

Chapter 2: CRP-guided Antibiotic Treatment in acute 27

exacerbations of COPD admitted to Hospital

Chapter 2.1: Safety of CRP-guided antimicrobial treatment in 49

hospitalized AECOPD

Chapter 3: Blood eosinophilia as a marker of early and late 55

treatment failure in severe acute exacerbations of COPD

Chapter 4: Role of low dose computed tomography scans 71

and biomarkers in patients hospitalized with acute exacerbations of COPD

Chapter 5: COPD-Lower Respiratory Tract infection Visual 85

Analogue Score (c-LRTI-VAS) validation in stable and exacerbated COPD patients

Chapter 6: Effects of doxycycline on local and systemic 103

inflammation in stable COPD patients, a randomized clinical trial

Chapter 7: General conclusion and future perspectives 121

Chapter 8: Summary 143

Chapter 9: Nederlandse samenvatting voor niet-ingewijden 149

Chapter 10: Curriculum Vitae 159

Chapter 11: Dankwoord 163

Referenties

GERELATEERDE DOCUMENTEN

public participation can provide a very useful component for the development of data sets to be used as input for risk studies at community level, and as a basis for risk

Chronic obstructive pulmonary disease (COPD) is defined as ‘a common, preventable and treatable disease that is characterised by persistent respiratory symptoms and airflow

14 We therefore hypothesized that CRP-guided antibiotic therapy may lead to a reduction of antibiotic therapy within 24 hours after admission compared to patient reported

First, in our study population, there was no significant difference in failure rates at days 10 and 30 between the CRP and GOLD group - which strongly argues against their point

This study demonstrates two important new findings related to blood eosinophilia, which was present in 19% of patients with an AECOPD at presentation to the hospital

However in this study we were not able to show effect of a 3 week course of doxycycline on sputum MPO, or on any of the other sputum and serum inflammatory markers as well as

However it has recently been reported that patients with AECOPD who have high bacterial sputum load during AECOPD had a significant decrease in blood eosinophilic count compared

In chapter 6 we present the results of an exploratory double blind randomized controlled trial investigating the effect of a 3-week course of doxycycline on sputum and